Identification of gene regulatory networks affected across drug-resistant epilepsies

• Published in: Nature communications 2024-03, Vol.15 (1), p.2180-2180, Article 2180
• Main Authors: François, Liesbeth, Romagnolo, Alessia, Luinenburg, Mark J., Anink, Jasper J., Godard, Patrice, Rajman, Marek, van Eyll, Jonathan, Mühlebner, Angelika, Skelton, Andrew, Mills, James D., Dedeurwaerdere, Stefanie, Aronica, Eleonora
• Format: Article
• Language: English
• Subjects: 13/89; 14/32; 49/91; 631/378/1689/178; 631/378/2583; Drug resistance; Drug Resistant Epilepsy - drug therapy; Drug Resistant Epilepsy - genetics; Energy metabolism; Epilepsy; Epilepsy, Temporal Lobe - drug therapy; Epilepsy, Temporal Lobe - genetics; Extracellular matrix; Gene Regulatory Networks; Hippocampus; Hippocampus - metabolism; Humanities and Social Sciences; Humans; Inflammation; multidisciplinary; Neuroplasticity; Neurotransmission; Pathology; Science; Science (multidisciplinary); Sclerosis; Seizures; Seizures - metabolism; Synaptic plasticity; Temporal lobe; TOR protein; Transcriptomes
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-024-46592-2

Epilepsy is a chronic and heterogenous disease characterized by recurrent unprovoked seizures, that are commonly resistant to antiseizure medications. This study applies a transcriptome network-based approach across epilepsies aiming to improve understanding of molecular disease pathobiology, recognize affected biological mechanisms and apply causal reasoning to identify therapeutic hypotheses. This study included the most common drug-resistant epilepsies (DREs), such as temporal lobe epilepsy with hippocampal sclerosis (TLE-HS), and mTOR pathway-related malformations of cortical development (mTORopathies). This systematic comparison characterized the global molecular signature of epilepsies, elucidating the key underlying mechanisms of disease pathology including neurotransmission and synaptic plasticity, brain extracellular matrix and energy metabolism. In addition, specific dysregulations in neuroinflammation and oligodendrocyte function were observed in TLE-HS and mTORopathies, respectively. The aforementioned mechanisms are proposed as molecular hallmarks of DRE with the identified upstream regulators offering opportunities for drug-target discovery and development. Epilepsy is a chronic, heterogeneous disease with an urgent need for novel therapies. Here, the authors show a systematic comparison of the global molecular signature of refractory epilepsies elucidating the key mechanisms of the disease pathology.